drugset / Trial / NCT05417126
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and effects of a single intravitreal injection of virally-carried Multi-Characteristic Opsin (vMCO-010) in Subjects with Stargardt Disease
Timeline
- Start
- 2022-07-05
- Primary completion
- 2023-08-02
- Completion
- 2023-09-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | vMCO-010 | Gene therapy (AAV / viral vector) | 1.2e+11 vg | Intravitreal |